Standardized triage reshapes how tricuspid regurgitation is evaluated before intervention
Tricuspid regurgitation has spent years in the shadow of left-sided valve disease, often followed conservatively until symptoms, right-sided remodeling, or end-organ congestion become difficult to ignore. The new stepwise framework described in European Heart Journal pushes back against that delayed trajectory by organizing evaluation from the first referral site through the expert heart valve centre. The central message is straightforward: the choice between medical therapy, surgery, or transcatheter treatment cannot rest on a single echocardiographic snapshot. It requires a structured reading of the lesion, the patient, and the physiologic burden carried by the right heart.
This matters because TR is rarely an isolated problem. Its severity is shaped by annular dilation, leaflet malcoaptation, right ventricular remodeling, pulmonary pressures, atrial fibrillation, prior left-sided valve disease, and the broader cardiometabolic state of the patient. A system that sorts those variables early makes it more likely that the patient reaches the right therapy while anatomy and ventricular reserve are still usable. Once congestion, hepatic dysfunction, renal impairment, and advanced right ventricular failure dominate the picture, procedural options narrow quickly.
Referral-center assessment begins with the mechanism, not the label
The review organizes the first stage of assessment around clinical and biological characterization. That starts with identifying the likely mechanism of TR, because functional, secondary, and device-related pathways do not behave the same way and do not lead to the same therapeutic path. A person with longstanding atrial fibrillation and annular dilation raises different questions from a patient with pacemaker lead interference or from one with pulmonary hypertension and right ventricular pressure overload.
Clinical assessment also needs to document the downstream effects of chronic venous congestion. Edema, ascites, hepatic congestion, exercise intolerance, renal dysfunction, and frailty all carry practical weight when procedural candidacy is discussed. Laboratory data are not treated as a side issue in this framework; they help identify organ injury that may influence timing and risk. In advanced TR, the valve lesion and the systemic consequences evolve together, and a referral pathway that ignores that link can miss the window when intervention still offers durable benefit.
Multimodality imaging defines anatomy, severity, and procedural feasibility
Echocardiography remains the first-line imaging tool, but the review makes clear that it cannot be the only one. A complete evaluation often demands a multimodality approach that includes echocardiography, computed tomography, and cardiac magnetic resonance. Each modality answers a different clinical question. Echocardiography is central for grading severity, understanding valve mechanics, and estimating chamber response. CT adds precision for annular dimensions, leaflet relationships, and structural planning. Cardiac magnetic resonance can sharpen the assessment of right ventricular size and function, a particularly important issue when symptoms and anatomy do not align cleanly.
This layered imaging strategy is especially relevant for transcatheter therapies, where feasibility depends on more than regurgitant jet grade. Coaptation gap, leaflet tethering, annular enlargement, and the spatial relationship to device structures all influence whether repair or replacement is technically realistic. A patient may appear suitable in principle but prove unsuitable once the anatomy is measured carefully. Another patient with apparently severe disease may turn out to be a better candidate than expected if the imaging profile matches the available device platform.
Hemodynamic testing closes the gap between echo and physiology
Invasive evaluation enters the pathway when noninvasive data are insufficient or when pulmonary pressures and filling conditions need clarification. The framework places invasive haemodynamic evaluation within the structured work-up because TR is often inseparable from broader right-sided pressure and flow abnormalities. The practical purpose is to avoid therapeutic decisions based on incomplete physiology. Severe venous congestion, borderline pulmonary vascular disease, or mixed valvular pathology can all alter candidacy and influence whether intervention is likely to improve symptoms or simply shift the problem downstream.
Hemodynamic data also help resolve discordance between symptoms and imaging. A patient with marked fatigue and edema may have deceptively modest resting findings, while another with impressive Doppler abnormalities may still have preserved reserve. In such cases, pressure measurements and filling assessments add a necessary layer of decision support. They do not replace imaging; they complete it.
Heart valve centres depend on coordinated expertise, not isolated interpretation
The review places heavy emphasis on multidisciplinary collaboration inside the expert heart valve centre. That includes imagers, heart failure specialists, interventional cardiologists, electrophysiologists, and surgeons working from the same diagnostic frame. The reason is clinical, not administrative. TR often sits at the intersection of rhythm disease, device therapy, ventricular dysfunction, and structural intervention. No single specialty holds all the relevant information.
A patient with atrial functional TR may need rhythm control strategy and valve evaluation in parallel. A patient with a transvalvular lead may require electrophysiology input before any structural intervention can be finalized. A patient with advanced right ventricular dysfunction may need heart failure expertise to judge whether symptoms are still reversible. Surgical risk, transcatheter feasibility, and expected benefit become much easier to weigh when those perspectives are assembled before treatment is chosen.
The review aligns this pathway with the 2025 ESC/EACTS guidelines for valvular heart disease, which further legitimizes a standardized referral model. In practice, standardization means that patients are not filtered through ad hoc local habits. They move through a repeatable sequence: mechanism, severity, chamber response, hemodynamics, operative risk, and anatomic feasibility. Each step reduces uncertainty and improves the chance that intervention is delivered at the right stage of disease.
A single sentence captures the clinical stakes: delayed referral can convert a potentially treatable valve lesion into advanced right heart failure.
Why the stepwise model may change bedside decision-making
The value of this framework is not abstraction. It gives clinicians a reproducible way to decide who should be observed, who should be referred, and who should be considered for structural intervention without unnecessary delay. That is especially important in TR, where under-recognition has historically translated into late presentation and limited therapeutic choices. A more disciplined pathway may also improve consistency across centres, reducing the variability that has long complicated TR care.
There is also a biological logic to the sequence. As TR worsens, the right ventricle and venous system face chronic volume overload. Over time, that burden drives dilation, decreases forward flow, and amplifies systemic congestion. If treatment arrives before irreversible remodeling dominates, repair or replacement has a better chance of relieving symptoms and preserving organ function. If it arrives too late, anatomy and physiology may already have crossed into a less reversible phase.
For clinicians, the message is to treat TR as a condition that deserves the same structured attention routinely given to aortic or mitral disease. The review does not introduce a single new device or randomized endpoint. Its contribution is organizational and clinical: a clearer pathway from referral to expert assessment, built to make advanced therapy more timely and more consistent. The remaining challenge is implementation, because a standardized algorithm only helps when patients with suspected TR are identified early enough to enter it.